Administrative Incidence and Prevalence of Multiple Myeloma Using Administrative Claims Data From a Large Health Maintenance Organization in Colombia, 2015–2023
Author(s)
Jair A. Arciniegas, MSc1, Juan Manuel Reyes Sanchez, MSc1, Farley Gonzalez, MSc2, Luz E. Perez Jaramillo, MSc2, Carlos Bello, Pharm2, Andreina J. Alamo, BSc1, Mónica García, MSc1, Brigitte Alejandra Alarcon, MD1, Jhon E. Bolaños, MSc, MD2, Leonardo Jose Enciso Olivera, MD2;
1Pfizer, Bogotá, Colombia, 2Biociencias-Sura, Medellín, Colombia
1Pfizer, Bogotá, Colombia, 2Biociencias-Sura, Medellín, Colombia
Presentation Documents
OBJECTIVES: This study aims to estimate the administrative incidence and prevalence of multiple myeloma (MM) from a Colombian Health Maintenance Organization (HMO) between 2015-2023.
METHODS: A retrospective database study was conducted in a large HMO with nationwide coverage for more than 5 million members in Colombia. MM was defined by cross-linking data in the HMO records using the ICD-10th code for MM (C90.0). The first recorded MM diagnosis was defined as the index date. Administrative prevalence and incidence were estimated based on the number of cases and new cases each year from the consultation register in the database over the total number of insured adults in the HMO per 100,000 members.
RESULTS: Administrative incident cases ranged from 89 (observed in 2016) to 624 cases (observed in 2022). Per 100,000 adults, the incidence was 7.16 cases in 2015. After a decrease to 4.34 cases in 2016, the incidence rose every year until 2022 (14.98 cases) before falling slightly to 12.85 in 2023. This represents a 79.5% increase in incidence from 2015 to 2023. On the other hand, the administrative prevalence cases surged from 282 cases in 2015 to 3,039 cases in 2023. This sharp increase in administrative prevalence, resembles the behavior of a concave pattern, considering it started in 15.18 cases in 2015 and ending at 70.53 cases per 100,00 adults, which represents a 364.6% increase.
CONCLUSIONS: Trends in incidence and administrative prevalence of MM between 2015 and 2023 in Colombia have been increasing, with a more marked pattern in prevalence, which has tripled since 2015.
METHODS: A retrospective database study was conducted in a large HMO with nationwide coverage for more than 5 million members in Colombia. MM was defined by cross-linking data in the HMO records using the ICD-10th code for MM (C90.0). The first recorded MM diagnosis was defined as the index date. Administrative prevalence and incidence were estimated based on the number of cases and new cases each year from the consultation register in the database over the total number of insured adults in the HMO per 100,000 members.
RESULTS: Administrative incident cases ranged from 89 (observed in 2016) to 624 cases (observed in 2022). Per 100,000 adults, the incidence was 7.16 cases in 2015. After a decrease to 4.34 cases in 2016, the incidence rose every year until 2022 (14.98 cases) before falling slightly to 12.85 in 2023. This represents a 79.5% increase in incidence from 2015 to 2023. On the other hand, the administrative prevalence cases surged from 282 cases in 2015 to 3,039 cases in 2023. This sharp increase in administrative prevalence, resembles the behavior of a concave pattern, considering it started in 15.18 cases in 2015 and ending at 70.53 cases per 100,00 adults, which represents a 364.6% increase.
CONCLUSIONS: Trends in incidence and administrative prevalence of MM between 2015 and 2023 in Colombia have been increasing, with a more marked pattern in prevalence, which has tripled since 2015.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EPH57
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
SDC: Oncology